Transgenic Mice Expressing Mutant Protein Kinase C lota in the Colonic Epithelium

Reference #:

2003-222

Inventors/Contributors

Alan P. Fields, Ph.D., Lee Jamieson, Nicole R. Murray, Ph.D., Melody L. Stallings-Mann, Ph.D.

Description

Atypical Protein Kinase-C iota (PKCi) has been implicated as an oncogene in several cancer types. Mayo Clinic researchers have utilized multiple screening systems to identify small molecule inhibitors of PKCi which have been tested in animal cancer models. Application Treatment of human cancers that involve PKCi signaling Stage of Development A Phase I clinical trial has been conducted in patients with advanced non-small cell lung carcinoma on an identified inhibitor. Screening studies for additional inhibitors are ongoing with multiple cancer types being assessed in animal models.

Patent Status

	U.S. Patent Number 7,642,400 Issued January 05, 2010